BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng J, Hamilton Z, Smyth M, Barker C, Israel D, Jacobson K. Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:1762-73. [DOI: 10.1097/mib.0000000000001212] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 van Rheenen H, van Rheenen PF. Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies. Pediatr Gastroenterol Hepatol Nutr 2020;23:121-31. [PMID: 32206624 DOI: 10.5223/pghn.2020.23.2.121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
3 Shimizu H, Arai K, Takeuchi I, Minowa K, Hosoi K, Sato M, Oka I, Kaburaki Y, Shimizu T. Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan. Pediatr Gastroenterol Hepatol Nutr 2021;24:7-18. [PMID: 33505889 DOI: 10.5223/pghn.2021.24.1.7] [Reference Citation Analysis]
4 Kim ES, Choi S, Choi SY, Park JH, Choe BH, Lee SY, Kim MJ, Choe YH, Kang B. NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine. Aliment Pharmacol Ther 2022. [PMID: 35032047 DOI: 10.1111/apt.16769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lyles JL, Mulgund AA, Bauman LE, Su W, Fei L, Chona DL, Sharma P, Etter RK, Hellmann J, Denson LA, Minar P, Dykes DM, Rosen MJ. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:482-92. [PMID: 32448898 DOI: 10.1093/ibd/izaa102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Batra S, Conklin LS. Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm. Handb Exp Pharmacol 2020;261:363-75. [PMID: 31342277 DOI: 10.1007/164_2019_255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]